We are live on ! Find out more
KLRS

Kalaris Therapeutics
KLRS

58 hedge funds and large institutions have $107M invested in Kalaris Therapeutics in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 7

114% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 7

14% more funds holding

Funds holding: 51 → 58 (+7)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

15.19% less ownership

Funds ownership: 96.22% → 81.03% (-15%)

29% less capital invested

Capital invested by funds: $152M → $107M (-$44.7M)

Holders
58
Holders Change
+7
Holders Change %
+13.73%
% of All Funds
0.71%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
15
Increased
16
Reduced
7
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PBM
Propel Bio Management
California
+$2.25M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$1.5M
3
Goldman Sachs
Goldman Sachs
New York
+$676K
4
SAM
Simplify Asset Management
Nevada
+$598K
5
Millennium Management
Millennium Management
New York
+$528K

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$700K
2
6CM
683 Capital Management
New York
-$316K
3
Jane Street
Jane Street
New York
-$279K
4
OAC
OMERS Administration Corp
Ontario, Canada
-$253K
5
Renaissance Technologies
Renaissance Technologies
New York
-$192K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$221K +$92.3K +10,396 +37%
VFT
27
Vanguard Fiduciary Trust
Pennsylvania
$212K +$326K +36,717 New
BlackRock
28
BlackRock
New York
$208K -$21.4K -2,411 -6%
Two Sigma Investments
29
Two Sigma Investments
New York
$177K +$25.7K +2,891 +10%
State Street
30
State Street
Massachusetts
$153K +$9.76K +1,100 +4%
BCM
31
Bridgeway Capital Management
Texas
$130K – – –
SCM
32
Stonepine Capital Management
Oregon
$118K +$181K +20,400 New
VCIM
33
Velan Capital Investment Management
Georgia
$104K +$160K +18,000 New
RC
34
RBF Capital
California
$100K – – –
Northern Trust
35
Northern Trust
Illinois
$83.4K +$7.06K +795 +6%
IAA
36
Independent Advisor Alliance
North Carolina
$82.1K +$126K +14,230 New
Connor, Clark & Lunn Investment Management (CC&L)
37
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$78.8K +$31K +3,496 +34%
WAM
38
WealthTrust Asset Management
Florida
$71.6K +$110K +12,416 New
HF
39
HRT Financial
New York
$67K +$103K +11,617 New
Qube Research & Technologies (QRT)
40
Qube Research & Technologies (QRT)
United Kingdom
$64.1K +$98.5K +11,103 New
JFGIW
41
Johnson Financial Group Inc (Wisconsin)
Wisconsin
$57.7K – – –
Citigroup
42
Citigroup
New York
$50.2K +$77.2K +8,702 +870,200%
Fidelity Investments
43
Fidelity Investments
Massachusetts
$45K – – –
UBS Group
44
UBS Group
Switzerland
$35.7K +$31K +3,493 +130%
Barclays
45
Barclays
United Kingdom
$30.5K -$6.97K -785 -13%
NCNMGF
46
Nano-Cap New Millennium Growth Fund
New York
$23.1K – – –
SPIA
47
Steward Partners Investment Advisory
New York
$12.8K +$19.7K +2,215 New
VGA
48
Vanguard Global Advisers
Pennsylvania
$4.18K +$6.43K +725 New
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$3.76K +$5.33K +600 +1,154%
SFCL
50
Strengthening Families & Communities LLC
Massachusetts
$1.55K +$2.38K +268 New
1
2
3

KLRS Hedge Fund Activity: Q1 2026 in Review

58 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q1 2026, worth a combined $107M — down 29% from $152M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new KLRS positions and 7 closed out — a net gain of 8 holders — while 16 added to existing stakes and 7 trimmed.

The largest buyer was Propel Bio Management, adding an estimated $2.25M. The largest seller was Redmile Group, exiting entirely with an estimated $700K sold.

  • 58 institutional investors held Kalaris Therapeutics (KLRS) as of Q1 2026, up from 51 in Q4 2025.
  • Funds reported $107M of Kalaris Therapeutics stock for Q1 2026, down 29% quarter-over-quarter.
  • 15 funds opened new Kalaris Therapeutics positions in Q1 2026 and 7 closed out, a net change of +8 holders.
  • The largest Kalaris Therapeutics buyer in Q1 2026 was Propel Bio Management, an estimated $2.25M added.
  • The largest Kalaris Therapeutics seller in Q1 2026 was Redmile Group, an estimated $700K sold.

Based on aggregated 13F filings for Q1 2026.